Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing...
Hence then, the article about johnson johnson therapy nipocalimab granted u s fda fast track designation in systemic lupus erythematosus sle was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) )
Also on site :
- 'Love on the Spectrum' Star Abbey Romeo Tasting Banana Foster at the Celebrity Chef Gala Is Every Millennial Ever
- BLUETTI Showcases Integrated PAYGO Energy Solution at Canton Fair, Expanding Partnership Opportunities in Africa
- Sandra Bullock Shares Thoughts on AI and Says ‘We Have to Make It Our Friend’ and ‘Lean Into It’